Harvard Bioscience, Inc. (HBIO): Price and Financial Metrics


Harvard Bioscience, Inc. (HBIO)

Today's Latest Price: $3.21 USD

0.10 (3.22%)

Updated Aug 3 8:00pm

Add HBIO to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 58 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

HBIO Stock Summary

  • With a year-over-year growth in debt of -12.48%, Harvard Bioscience Inc's debt growth rate surpasses merely 18.77% of about US stocks.
  • Over the past twelve months, HBIO has reported earnings growth of -403.17%, putting it ahead of only 4.59% of US stocks in our set.
  • The volatility of Harvard Bioscience Inc's share price is greater than that of merely 22.17% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Harvard Bioscience Inc are BDC, VAPO, STIM, LNDC, and CAMP.
  • HBIO's SEC filings can be seen here. And to visit Harvard Bioscience Inc's official web site, go to www.harvardbioscience.com.
HBIO Daily Price Range
HBIO 52-Week Price Range

HBIO Stock Price Chart Technical Analysis Charts


HBIO Price/Volume Stats

Current price $3.21 52-week high $3.77
Prev. close $3.11 52-week low $1.39
Day low $3.04 Volume 125,000
Day high $3.21 Avg. volume 233,295
50-day MA $3.07 Dividend yield N/A
200-day MA $2.82 Market Cap 123.20M

Harvard Bioscience, Inc. (HBIO) Company Bio


Harvard Bioscience, Inc. develops, manufactures, and markets scientific instruments, systems, and lab consumables used in life science research. The company was founded in 1901 and is based in Holliston, Massachusetts.

HBIO Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$3.21$2.52 -19%

Below please find a table outlining a discounted cash flow forecast for HBIO, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Harvard Bioscience Inc ranked in the 43th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Harvard Bioscience Inc ended up being:

  • The company's balance sheet shows it gets 67% of its capital from equity, and 33% of its capital from debt. Notably, its equity weight is greater than only 23.81% of US equities in the Healthcare sector yielding a positive free cash flow.
  • Harvard Bioscience Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -0.54. This coverage rate is greater than that of merely 22.02% of stocks we're observing for the purpose of forecasting via discounted cash flows.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-21%
1%-20%
2%-19%
3%-18%
4%-17%
5%-17%

Want more companies with a valuation profile/forecast similar to that of Harvard Bioscience Inc? See ICLR, DGX, GILD, CRL, and CAH.





HBIO Latest News Stream


Event/Time News Detail
Loading, please wait...

HBIO Latest Social Stream


Loading social stream, please wait...

View Full HBIO Social Stream

Latest HBIO News From Around the Web

Below are the latest news stories about Harvard Bioscience Inc that investors may wish to consider to help them evaluate HBIO as an investment opportunity.

Harvard Bioscience Schedules Second Quarter 2020 Earnings Conference Call for August 5, 2020 at 8:00 AM ET

HOLLISTON, Mass., July 20, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for second quarter ended…

GlobeNewswire | July 20, 2020

Hedge Funds Are Dumping Harvard Bioscience, Inc. (HBIO)

How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]

Yahoo | July 5, 2020

Avidity Biosciences, Enviva Partners See Activist Action

RTW Investments disclosed an 11.3% stake in newly public biopharmaceutical firm Avidity. ValueAct Capital raised its stake in biomass firm Enviva.

Yahoo | June 27, 2020

Edited Transcript of HBIO earnings conference call or presentation 5-May-20 12:00pm GMT

Q1 2020 Harvard Bioscience Inc Earnings Call

Yahoo | June 12, 2020

Harvard Bioscience, Inc. Issues Letter to Shareholders

Jim Green, Chairman, President & Chief Executive Officer of Harvard Bioscience, Inc. (HBIO) (the “Company” or “Harvard Bioscience”), today issued a letter to shareholders updating them on the Company’s execution against the key strategic actions committed to in September 2019 to position Harvard Bioscience for long-term profitable growth. In addition, we expect to complete the streamlining of our UK operation next quarter.

Yahoo | May 26, 2020

Read More 'HBIO' Stories Here

HBIO Price Returns

1-mo N/A
3-mo 27.89%
6-mo 8.08%
1-year 38.96%
3-year 5.25%
5-year -30.07%
YTD 5.25%
2019 -4.09%
2018 -3.64%
2017 8.20%
2016 -12.10%
2015 -38.80%

Continue Researching HBIO

Want to see what other sources are saying about Harvard Bioscience Inc's financials and stock price? Try the links below:

Harvard Bioscience Inc (HBIO) Stock Price | Nasdaq
Harvard Bioscience Inc (HBIO) Stock Quote, History and News - Yahoo Finance
Harvard Bioscience Inc (HBIO) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8559 seconds.